Part 4 – Single-cell expression profiling of mesenchymal stromal cells: Initial experience using BD Rhapsody™
In the fourth and final seminar from the BD Multi-Omics user meeting, Dr. Alison Devonshire from the National Measurement Laboratory, United Kingdom, talks about the use of the BD Multi-Omics technology for the expression profiling of mesenchymal stromal cells (MSC). MSCs are plastic-adherent, multipotent, self-renewing cells that express a specific set of cell-surface antigens that can differentiate into adipocytes, chondrocytes and osteocytes when cultured in-vitro.1 They can also be both pro- and anti-inflammatory, and can migrate and support tumorigenesis. The minimal criteria for defining MSC markers have been laid down by the International Society of Cellular Therapy (ISCT).2 However, many of the suggested markers are controversial (CD34), heterogeneous or found in contaminating cultures.
As a part of the project ‘De-risking of Regenerative Medicine’, Dr. Devonshire and her team have attempted to define new critical quality attributes (CQA) for MSCs . They have also attempted to monitor the stability of MSC associated markers and the response to inflammatory cytokines. Following the identification of cells with ISCT positive and negative markers using improved barcoding techniques, Dr. Devonshire and her team have used the BD Rhapsody™ Human Immune Response Panel to evaluate the expression of numerous genes. In addition to single-cell RNA sequencing, they also used flow cytometry and secretory profiles to evaluate marker expression. They have concluded that the BD Rhapsody™ Human Immune Response Panel shows promise in monitoring a range of CQAs for stem-cell-based products.